27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
(Biotech stocks hitting 52-week highs on Oct. 1)
- Boston Scientific Corporation (NYSE:BSX)
- Eli Lilly And Co (NYSE:LLY)
- Masimo Corporation (NASDAQ:MASI)
- Merck & Co., Inc. (NYSE:MRK)
- Merit Medical Systems, Inc. (NASDAQ:MMSI)
- Trevena Inc (NASDAQ:TRVN)
- Urovant Sciences Ltd. (NASDAQ:UROV)
Down In The Dumps
(Biotech stocks hitting 52-week lows on Oct. 1)
- Arvinas Inc (NASDAQ:ARVN)
- Avrobio Inc (NASDAQ:AVRO)
- Genprex Inc (NASDAQ:GNPX)
- Gritstone Oncology, Inc. (NASDAQ:GRTS)
- GTx, Inc. (NASDAQ:GTXI)
- Kala Pharmaceuticals Inc (NASDAQ:KALA)
- La Jolla Pharmaceutical Company (NASDAQ:LJPC)
- Magenta Therapeutics Inc (NASDAQ:MGTA)
- OptiNose Inc (NASDAQ:OPTN)
- REALM THERAPEUTICS ADR (NASDAQ:RLM)
- Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)
- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
- Vital Therapies Inc (NASDAQ:VTL)
See Also: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates
Stocks In Focus
Endologix Expects Q3 Revenues Above Consensus; Raises Low-End Of FY18 Revenue Guidance
Endologix, Inc. (NASDAQ:ELGX) announced preliminary third-quarter results, expecting revenues in the range of $34.3 million to $34.7 million, ahead of the $31.13 million consensus estimate. Citing the current business trends, the company raised the low-end of its 2018 revenue guidance to $150 million from $145 million, while maintaining the high-end at $155 million.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The stock soared 37.21 percent to $2.36 in after-hours trading.
Novartis Out-Licenses 3 Anti-Infectives
Novartis AG (NYSE:NVS) said it licensed three novel anti-infective drug candidates to Boston Pharma. These pipeline assets have the potential to treat antibiotic-resistant Gram-negative infections.
Obseva Reports Additional Positive Data For Nolasiban
Obseva SA (NASDAQ:OBSV) released additional positive Phase 3 data from the IMPLANT 2 trial of its oral, oxytocin receptor antagonist Nolasiban in patients undergoing IVF procedures. The data showed that the candidate significantly increased live birth rate following IVF treatment.
An additional Phase 3 trial is set to begin prior to the end of 2018 and is expected to generate primary endpoint, 10-week ongoing pregnancy data, in about 12 months, allowing for a planned MAA submission in Europe by the end of 2019.
Offerings
Epizyme Inc (NASDAQ:EPZM) priced its underwritten public offering of 8.33 million shares of its common stock at $9 per share, a discount to Tuesday's closing price of $9.71. All the shares are to be sold by the company. The company expects gross proceeds of $75 million from the offering.
The stock shed 7.31 percent to $9 in after-hours trading.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) priced its previously announced offering of 1.90 million ADSs, representing 22.8 million ordinary shares, at a price of $158 per ADS. The company expects to raise gross proceeds of about $300 million from the offering.
Kala Pharma said it commenced an underwritten public offering of 7.50 million shares. Separately, the company said it closed its $110 million credit facility with funds managed by Athyrium Capital Management.
The stock fell 9.48 percent to $8.40 in after-hours trading.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.